Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/309% below fair value
$2.83+0.10 (+3.86%)
Close on Nov 18, 2026Market cap $1.51BP/E –Yield –
Recursion Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Recursion Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $54.86M, down 15.1% year over year. For fiscal 2025 it was $74.68M, up 26.9% from the year before. The highest annual figure on record is $74.68M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.68M | +26.9% |
| FY2024 | Dec 31, 2024 | $58.84M | +32.0% |
| FY2023 | Dec 31, 2023 | $44.58M | +11.9% |
| FY2022 | Dec 31, 2022 | $39.84M | +291.5% |
| FY2021 | Dec 31, 2021 | $10.18M | +156.9% |
| FY2020 | Dec 31, 2020 | $3.96M | +70.8% |
| FY2019 | Dec 31, 2019 | $2.32M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.67M | -60.1% |
| Q1 FY2026 | Mar 31, 2026 | $6.47M | -56.1% |
| Q4 FY2025 | Dec 31, 2025 | $35.54M | +681.7% |
| Q3 FY2025 | Sep 30, 2025 | $5.18M | -80.2% |
| Q2 FY2025 | Jun 30, 2025 | $19.22M | +33.3% |
| Q1 FY2025 | Mar 31, 2025 | $14.75M | +6.9% |
| Q4 FY2024 | Dec 31, 2024 | $4.55M | -58.3% |
| Q3 FY2024 | Sep 30, 2024 | $26.08M | +147.6% |
| Q2 FY2024 | Jun 30, 2024 | $14.42M | +30.9% |
| Q1 FY2024 | Mar 31, 2024 | $13.79M | +13.7% |
| Q4 FY2023 | Dec 31, 2023 | $10.89M | -20.4% |
| Q3 FY2023 | Sep 30, 2023 | $10.53M | -20.0% |
| Q2 FY2023 | Jun 30, 2023 | $11.02M | +43.6% |
| Q1 FY2023 | Mar 31, 2023 | $12.13M | +127.5% |
| Q4 FY2022 | Dec 31, 2022 | $13.68M | +439.9% |
| Q3 FY2022 | Sep 30, 2022 | $13.16M | +419.3% |
| Q2 FY2022 | Jun 30, 2022 | $7.67M | +201.1% |
| Q1 FY2022 | Mar 31, 2022 | $5.33M | +108.2% |
| Q4 FY2021 | Dec 31, 2021 | $2.53M | -5.9% |
| Q3 FY2021 | Sep 30, 2021 | $2.53M | +147.2% |
| Q2 FY2021 | Jun 30, 2021 | $2.55M | +1270.4% |
| Q1 FY2021 | Mar 31, 2021 | $2.56M | +4170.0% |
| Q4 FY2020 | Dec 31, 2020 | $2.69M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.03M | – |
| Q2 FY2020 | Jun 30, 2020 | $186.00K | – |
| Q1 FY2020 | Mar 31, 2020 | $60.00K | – |
See a number that looks wrong?